Trials / Completed
CompletedNCT00316628
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | influenza vaccine |
Timeline
- Start date
- 2005-06-01
- First posted
- 2006-04-21
- Last updated
- 2006-09-14
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00316628. Inclusion in this directory is not an endorsement.